Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Benefit of paclitaxel-carboplatin lung cancer therapy linked to estrogen, study shows
March 16th, 2006
In a presentation at the BIO CEO & Investor conference, James A. Bianco, MD, president and CEO of Cell Therapeutics, Inc. (CTIC) presented updated results of a phase 2 study of Xyotax in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung cancer (NSCLC). Unlike the STELLAR 3 and 4 trials, where only patients with poor performance status (PS2) were enrolled, there was no restriction on performance status in the phase 2 trial, known as PGT202. The study was analyzed for overall survival by gender and by estrogen levels to confirm the observation of enhanced efficacy in the presence of estrogen seen in the STELLAR first-line...
Source: Women's Health Weekly (2006-03-16)
|
